Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Vertex Pharmaceuticals / Equity Bottom-Up

<ul><li>During Vertex Pharmaceuticals' Fourth Quarter 2023 Earnings Call, the company highlighted the achievements of the past year, including the strong financial results they achieved and the progress of their various drug development programs.</li><li>Vertex continued its impressive growth streak, achieving full year CF product revenues of $9.87 billion, which represents an 11% growth from 2022.</li><li>The company attributes this growth primarily to the increased number of CF patients being reached and the groundbreaking approvals of CASGEVY, the first-ever CRISPR/Cas9-based therapy.</li></ul>

During Vertex Pharmaceuticals' Fourth Quarter 2023 Earnings Call, the company highlighted the achievements of the past year, including the strong financial results they achieved and the progress of their various drug development programs.Vertex continued its impressive growth streak, achieving full year CF product revenues of $9.87 billion, which represents an 11% growth from 2022.The company attributes this growth primarily to the increased number of CF patients being reached and the groundbreaking approvals of CASGEVY, the first-ever CRISPR/Cas9-based therapy.

Vertex Pharmaceuticals: Commercial Launch of CASGEVY

<ul><li>Vertex Pharmaceuticals delivered a mixed set of results for the previous quarter, with revenues below the analyst consensus.</li><li>In the third quarter, Vertex witnessed a commendable 6% growth in global product revenue compared to the previous year.</li><li>In this report, we have carried out a fundamental analysis of the historical financial statements of the company.</li></ul>

Vertex Pharmaceuticals delivered a mixed set of results for the previous quarter, with revenues below the analyst consensus.In the third quarter, Vertex witnessed a commendable 6% growth in global product revenue compared to the previous year.In this report, we have carried out a fundamental analysis of the historical financial statements of the company.

Vertex Pharmaceuticals: Diversifying Beyond Cystic Fibrosis – The Next Big Leap? - Major Drivers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/vertex-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:4864:1" rel="noopener">Vertex Pharmaceuticals (VRTX US)</a> is expanding its pipeline beyond its existing forte of cystic fibrosis, which enhances its long-term visibility.</li>
<li>Gene editing treatment CTX001 for treating sickle cell disease and beta thalassemia is Vertex’s most advanced program outside of CF. With its initial label approval, CTX001 has multi-billion-dollar opportunity.</li>
<li>A war chest of $7.5 billion and stable revenue flow from cystic fibrosis drugs should enable the company to pursue for the next leg of growth.</li>
</ul>



Vertex Pharmaceuticals (VRTX US) is expanding its pipeline beyond its existing forte of cystic fibrosis, which enhances its long-term visibility.
Gene editing treatment CTX001 for treating sickle cell disease and beta thalassemia is Vertex’s most advanced program outside of CF. With its initial label approval, CTX001 has multi-billion-dollar opportunity.
A war chest of $7.5 billion and stable revenue flow from cystic fibrosis drugs should enable the company to pursue for the next leg of growth.


Vertex Pharmaceuticals (VRTX US): No Longer Remains a ‘Cystic Fibrosis Only’ Play

<ul><li>Vertex Pharmaceuticals delivered a solid result and managed an all-around beat last quarter.</li><li>The company's continued momentum in all aspects, particularly in the Cystic Fibrosis (CF) business, has led to solid growth in global product revenue.</li><li>Vertex has strategically invested in promising therapies for severe sickle cell disease, transfusion-dependent beta-thalassemia, acute pain relief, and CF treatments.</li></ul>

Vertex Pharmaceuticals delivered a solid result and managed an all-around beat last quarter.The company's continued momentum in all aspects, particularly in the Cystic Fibrosis (CF) business, has led to solid growth in global product revenue.Vertex has strategically invested in promising therapies for severe sickle cell disease, transfusion-dependent beta-thalassemia, acute pain relief, and CF treatments.

Vertex Pharmaceuticals: Exploring the Pipeline: From Pain Relief to Sickle Cell Miracles! - Major Drivers

Equity Capital Markets

Vertex Pharmaceuticals / Equity Capital Markets

<ul><li>Vertex started off with 2023 on a positive note as it delivered an all-around beat with first-quarter global CF product revenues increasing 13% over Q1 2022 levels.</li><li>Revenue for the first quarter rose 13% year over year to $2.37 billion.</li><li>In this regard, they are engaging with major commercial as well as government payers and policymakers in the U.S. and Europe.</li></ul>

Vertex started off with 2023 on a positive note as it delivered an all-around beat with first-quarter global CF product revenues increasing 13% over Q1 2022 levels.Revenue for the first quarter rose 13% year over year to $2.37 billion.In this regard, they are engaging with major commercial as well as government payers and policymakers in the U.S. and Europe.

Vertex Pharmaceuticals Incorporated: The TRIKAFTA Approval & Other Developments

United States

Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes novel, small molecule pharmaceuticals for the treatment of diseases for which there are currently limited or no effective treatments.  The Company develops drugs for the treatment of cystic fibrosis, autoimmune diseases, cancer, inflammatory bowel disease, and neurological disorders.

Vertex Pharmaceuticals (VRTX US)

Vertex Pharmaceuticals: Commercial Launch of CASGEVY

During Vertex Pharmaceuticals' Fourth Quarter 2023 Earnings Call, the company highlighted the achievements of the past year, including the strong...

Baptista Research

Vertex Pharmaceuticals: Diversifying Beyond Cystic Fibrosis – The Next Big Leap? - Major Drivers

Vertex Pharmaceuticals delivered a mixed set of results for the previous quarter, with revenues below the analyst consensus. In the third quarter,...

Baptista Research